These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9605749)

  • 21. DNA topoisomerases as repair enzymes: mechanism(s) of action and regulation by p53.
    Larsen AK; Gobert C; Gilbert C; Markovits J; Bojanowski K; Skladanowski A
    Acta Biochim Pol; 1998; 45(2):535-44. PubMed ID: 9821882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
    Roemer K
    Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.
    Pugacheva EN; Ivanov AV; Kravchenko JE; Kopnin BP; Levine AJ; Chumakov PM
    Oncogene; 2002 Jul; 21(30):4595-600. PubMed ID: 12096336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of p53 DNA binding activity by point mutation.
    Marston NJ; Ludwig RL; Vousden KH
    Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain.
    Mazur SJ; Sakaguchi K; Appella E; Wang XW; Harris CC; Bohr VA
    J Mol Biol; 1999 Sep; 292(2):241-9. PubMed ID: 10493872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
    Takimoto R; El-Deiry WS
    Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
    Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
    Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells.
    Kwon JA; Rho HM
    Biol Chem; 2003 Feb; 384(2):203-12. PubMed ID: 12675512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.
    Loging WT; Reisman D
    Oncogene; 1999 Dec; 18(52):7608-15. PubMed ID: 10602522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein.
    Huang P
    Oncogene; 1998 Jul; 17(3):261-70. PubMed ID: 9690508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional regulation of the human glycoprotein hormone common alpha subunit gene by cAMP-response-element-binding protein (CREB)-binding protein (CBP)/p300 and p53.
    Zhang X; Grand RJ; McCabe CJ; Franklyn JA; Gallimore PH; Turnell AS
    Biochem J; 2002 Nov; 368(Pt 1):191-201. PubMed ID: 12164786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
    Satyamoorthy K; Chehab NH; Waterman MJ; Lien MC; El-Deiry WS; Herlyn M; Halazonetis TD
    Cell Growth Differ; 2000 Sep; 11(9):467-74. PubMed ID: 11007451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
    Thomas S; Reisman D
    Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein.
    Orgad S; Goldfinger N; Cohen G; Rotter V; Solomon B
    FEBS Lett; 2005 Oct; 579(25):5609-15. PubMed ID: 16213502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.
    Stros M; Muselíková-Polanská E; Pospísilová S; Strauss F
    Biochemistry; 2004 Jun; 43(22):7215-25. PubMed ID: 15170359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
    Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
    Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
    Zavaglia D; Lin EH; Guidetti M; Pluquet O; Hainaut P; Favrot MC; Coll JL
    J Gene Med; 2005 Jul; 7(7):936-44. PubMed ID: 15754307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.
    Gobert C; Skladanowski A; Larsen AK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10355-60. PubMed ID: 10468612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
    El-Hizawi S; Lagowski JP; Kulesz-Martin M; Albor A
    Cancer Res; 2002 Jun; 62(11):3264-70. PubMed ID: 12036943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.